TNF Pharmaceuticals, Inc. Total Liabilities
TNF Pharmaceuticals, Inc. total liabilities. Based on the latest financial reports, TNF Pharmaceuticals, Inc. (TNFA) has total liabilities worth $5.55 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of TNF Pharmaceuticals, Inc. to evaluate the company's liquid asset resilience ratio.
Total Liabilities of TNF Pharmaceuticals, Inc. (2004–2024)
Total liabilities of TNF Pharmaceuticals, Inc. from 2004 to 2024. This chart illustrates how TNF Pharmaceuticals, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore TNFA long-term investment intensity to see how much of total assets are deployed in long-term investments.
TNF Pharmaceuticals, Inc. Competitors by Total Liabilities
The table below lists competitors of TNF Pharmaceuticals, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bell Copper Corp
V:BCU
|
Canada | CA$4.98 Million |
|
DGB Group NV
AS:DGB
|
Netherlands | €14.38 Million |
|
Pharmacielo Ltd
V:PCLO
|
Canada | CA$23.57 Million |
|
Rockworth Public Company Limited
BK:ROCK
|
Thailand | ฿526.74 Million |
|
Gafisa S.A
SA:GFSA3
|
Brazil | R$3.20 Billion |
|
Corella Resources Ltd
AU:CR9
|
Australia | AU$694.23K |
|
Micro Digital Co. Ltd
KQ:305090
|
Korea | ₩38.62 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down TNF Pharmaceuticals, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TNF Pharmaceuticals, Inc. balance sheet assets.
Liquidity & Leverage Metrics
TNF Pharmaceuticals, Inc. Total Liabilities Ratios Explained
TNF Pharmaceuticals, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TNF Pharmaceuticals, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TNF Pharmaceuticals, Inc. (2004–2024)
The table below shows the annual total liabilities of TNF Pharmaceuticals, Inc. from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.70 Million | +31.69% |
| 2023-12-31 | $5.09 Million | +78.87% |
| 2022-12-31 | $2.84 Million | +144.04% |
| 2021-12-31 | $1.17 Million | -48.49% |
| 2020-12-31 | $2.26 Million | +47.95% |
| 2019-12-31 | $1.53 Million | -22.48% |
| 2018-12-31 | $1.97 Million | +10.56% |
| 2017-12-31 | $1.79 Million | +5.16% |
| 2016-12-31 | $1.70 Million | +1.72% |
| 2015-12-31 | $1.67 Million | -9.50% |
| 2014-12-31 | $1.84 Million | -5.60% |
| 2013-12-31 | $1.95 Million | -7.57% |
| 2012-12-31 | $2.11 Million | +195.65% |
| 2011-12-31 | $714.78K | -43.76% |
| 2010-12-31 | $1.27 Million | +10.51% |
| 2009-12-31 | $1.15 Million | +15.48% |
| 2008-12-31 | $996.00K | -86.72% |
| 2007-12-31 | $7.50 Million | +32.22% |
| 2006-12-31 | $5.67 Million | +10.96% |
| 2005-12-31 | $5.11 Million | +19.53% |
| 2004-12-31 | $4.28 Million | -- |
About TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more